Prosecution Insights
Last updated: October 02, 2026
Application No. 17/775,206

CRISPR COMPLEX-BASED DETECTION SYSTEM AND METHOD

Non-Final OA §103§112§DOUBLEPATENT
Filed
May 06, 2022
Priority
Nov 08, 2019 — provisional 62/932,823 +8 more
Examiner
SALVOZA, M FRANCO G
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Florida Research Foundation Inc.
OA Round
3 (Non-Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
427 granted / 624 resolved
+8.4% vs TC avg
Strong +30% interview lift
Without
With
+30.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
52 currently pending
Career history
661
Total Applications
across all art units

Statute-Specific Performance

§101
9.8%
-30.2% vs TC avg
§103
27.8%
-12.2% vs TC avg
§102
9.2%
-30.8% vs TC avg
§112
29.1%
-10.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 624 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 8/4/2026 has been entered. 2. Claims 1, 6 are amended. Claims 3, 5, 19-21, 23, 25, 27 are canceled. Claims 22, 24, 26 are withdrawn. Claims 1, 2, 4, 6-18 are under consideration. Claim Rejections - 35 USC § 103 3. (previous rejection, withdrawn) Claims 1, 2, 4, 7-13, 16 were rejected under 35 U.S.C. 103 as being unpatentable over Doudna et al. (US20190241954) (cited in applicant's IDS submitted 5/6/2022) in view of Lee et al. (US20190218547)(cited in applicant's IDS submitted 5/6/2022). Applicant contends: claim 1 has been amended. In view of applicant’s amendments, the rejection is withdrawn. 4. (previous rejection, withdrawn) Claims 14, 15 were rejected under 35 U.S.C. 103 as being unpatentable over Doudna et al. in view of Lee et al. as applied to claims 1, 2, 4, 7-13, 16 above, and further in view of Liu et al. (CN111549177A; previously cited)(See also the WIPO English translation of CN111549177A; previously cited). In view of the withdrawal of the rejection over Doudna et al. in view of Lee et al. on which the instant rejection depends, the instant rejection is also withdrawn. Double Patenting 5. (previous rejection, withdrawn) Claims 1, 4, 7, 11 were provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 8, 10, 16, 19, 20, 30-32 of copending Application No. 17/928400 in view of Lee et al. (cited above). Applicant contends: claim 1 has been amended. In view of applicant’s amendments, the rejection is withdrawn. 6. Claims 1, 2, 4, 6-18 are allowable as to the elected species. Claims 22, 24, 26, previously withdrawn from consideration as a result of a restriction requirement, contain all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement as to inventions I and II and species, as set forth in the Office action mailed on 6/18/2025, is hereby withdrawn and claims 22, 24, 26 and additional species are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 7. (new rejection) Claims 22, 24, 26 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. See claims 22, 24, 26 as submitted 7/21/2026. Claim 22 recites “substantially complementary” as well as “substantially complementary … such that…” . It is unclear what the metes and bounds of “substantially” and thus its relation to the rest of the claim language are. Further, the claim recites “preferentially binds”. It is not clear if the subsequent language is actually a limitation or not. Conclusion 8. Claims 1, 2, 4, 6-18 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to M FRANCO G SALVOZA whose telephone number is (571)272-4468. The examiner can normally be reached M-F 8:00 to 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone can be reached at 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /M FRANCO G SALVOZA/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

May 06, 2022
Application Filed
Nov 19, 2025
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT
Feb 17, 2026
Response Filed
Jun 03, 2026
Final Rejection mailed — §103, §112, §DOUBLEPATENT
Jul 21, 2026
Response after Non-Final Action
Aug 04, 2026
Request for Continued Examination
Aug 05, 2026
Response after Non-Final Action
Sep 22, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735470
ENGINEERED T CELL RECEPTORS AND METHODS OF USE
3y 9m to grant Granted Sep 15, 2026
Patent 12703722
POPTAG PEPTIDE AND USES THEREOF
4y 2m to grant Granted Aug 11, 2026
Patent 12704516
METHODS AND COMPOSITIONS FOR RAPID DIRECT DETECTION AND DIFFERENTIATION OF INFECTIOUS FROM NONINFECTIOUS VIRUS
3y 8m to grant Granted Aug 11, 2026
Patent 12691171
CORONAVIRUS VACCINE FORMULATIONS
4y 0m to grant Granted Jul 28, 2026
Patent 12662674
RNA NANOPARTICLE FOR LIVER CANCER TREATMENT
4y 0m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
98%
With Interview (+30.0%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 624 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month